Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline - Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 bill

Related Keywords

Matthew Caufield ,Evan David Seigerman ,Andres Maldonado ,Trikafta Kaftrio ,Vertex Pharmaceuticals Inc ,Sananda Ghosh ,Joseph Stringer ,